KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Net Margin (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Net Margin for 16 consecutive years, with 5.33% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin fell 2204.0% year-over-year to 5.33%, compared with a TTM value of 10.83% through Dec 2025, down 413.0%, and an annual FY2025 reading of 10.83%, down 413.0% over the prior year.
  • Net Margin was 5.33% for Q4 2025 at Biomarin Pharmaceutical, down from 3.96% in the prior quarter.
  • Across five years, Net Margin topped out at 29.14% in Q2 2025 and bottomed at 12.87% in Q4 2021.
  • Average Net Margin over 5 years is 7.2%, with a median of 6.06% recorded in 2022.
  • The sharpest move saw Net Margin plummeted -17353bps in 2021, then skyrocketed 1968bps in 2022.
  • Year by year, Net Margin stood at 12.87% in 2021, then skyrocketed by 100bps to 0.05% in 2022, then surged by 6907bps to 3.15% in 2023, then surged by 430bps to 16.72% in 2024, then tumbled by -132bps to 5.33% in 2025.
  • Business Quant data shows Net Margin for BMRN at 5.33% in Q4 2025, 3.96% in Q3 2025, and 29.14% in Q2 2025.